The Journey to RSV Vaccines — Heralding an Era of Structure-Based Design
After a 1960s RSV vaccine was found to enhance disease in previously unexposed infants, development was put on hold. But structure-based design has led to effective RSV vaccines that now await approval.
Defining the Burden of Disease of RSV in Europe: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling study
RSV infections cause an estimated 22-50 million episodes of acute lower respiratory infections (ALRI) every year in children younger than 5 years.
A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine
This article assess the effect of RSV fusion protein (F) conformation on B cell responses in a post hoc comparison of samples from the DS-Cav1 [prefusion (pre-F)] and MEDI7510 [postfusion (post-F)] vaccine clinical trials.
Risk of Type 1 Diabetes in Children is Not Increased after SARS-CoV-2 Infection: A Nationwide Prospective Study in Denmark
It has been hypothesized that SARS-CoV-2 infection in children can increase risk of developing type 1 diabetes.
RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses
RSV infection in children is the most common viral respiratory infection and can cause severe lung damage or death. There is no licensed vaccine for preventing RSV infection.
News
Policy & Recommendations
COVI Committee at the European Parliament evaluates the socio-economic impact of the COVID-19 pandemic on children
Members of the European Parliament looked at the possible consequences to children's well-being, including their mental health.
Rate of Hospitalizations and Mortality of Respiratory Syncytial Virus Infection Compared to Influenza in Older People: A Systematic Review and Meta-Analysis
Since the data regarding the impact of RSV are still limited for older people, the aim of this systematic review and meta-analysis is to compare the rate of hospitalization and mortality between RSV and influenza in this population.
Respiratory Syncytial Virus Protects Bystander Cells against Influenza A Virus Infection by Triggering Secretion of Type I and Type III Interferons
We observed the interference between two prevalent respiratory viruses, respiratory syncytial virus (RSV) and influenza A virus (IAV) (H1N1), and characterized its molecular underpinnings in alveolar epithelial cells (A549).
The Health System Burden of RSV in Europe
European Health Management Association's (EHMA) white paper on the health system burden of the Respiratory syncytial virus (RSV) in Europe.
Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis
Respiratory syncytial virus (RSV)-associated acute respiratory infection (ARI) is an underrecognized cause of illness in older adults.
Respiratory tract infections in children - our paediatrician's insight and bold vision for the future
Her passion, love and interest to care for children is evident in this personal account by Paula Tähtinen, Clinical Lecturer, Paediatrics and Adolescent Medicine / Adjunct Professor, University of Turku, Finland and ESWI Board Member.
Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory infections in infants and the immunocompromised, yet no efficient therapeutic exists. We have identified the AVG class of allosteric inhibitors of RSV RNA synthesis.
